Albumin-Fused Antibodies May Reduce Fetal Exposure to Therapeutics
Preclinical study found that fusing immunoglobulin G (IgG) antibodies to albumin minimized antibody transport across the placenta and prevented adverse effects in offspring in mice, pointing to albumin as an attractive fusion partner for IgG-based therapeutics.